Bristol-Myers Squibb Clinical Trial Pipeline — 128 Active Studies

Bristol-Myers Squibb pipeline at a glance (March 2026)

About the Bristol-Myers Squibb clinical program

Bristol-Myers Squibb's clinical pipeline is defined by its foundational immuno-oncology franchise — Opdivo (nivolumab, PD-1) and Yervoy (ipilimumab, CTLA-4) — plus a growing cell therapy portfolio. The Opdivo + Yervoy combination remains one of the most broadly applied IO regimens in oncology, with ongoing trials across virtually every solid tumor type. In hematology, Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma and Abecma (idecabtagene vicleucel) for multiple myeloma represent BMS's CAR-T franchise, with active trials moving these therapies into earlier lines. Their cardiovascular drug mavacamten (Camzyos) and factor XIa inhibitor milvexian are advancing in a rejuvenated cardiovascular pipeline.

Key therapeutic areas

• Immuno-oncology (PD-1/CTLA-4)
• Cell therapy (CAR-T, lymphoma, myeloma)
• Hematology / combinations
• Cardiovascular (mavacamten, factor XIa)
• Fibrosis / inflammation

Key pipeline programs

• Opdivo (nivolumab) — PD-1, pan-tumor IO
• Yervoy (ipilimumab) — CTLA-4, IO combination
• Breyanzi (lisocabtagene maraleucel) — CD19 CAR-T, B-cell lymphoma
• Abecma (idecabtagene vicleucel) — BCMA CAR-T, myeloma
• Reblozyl (luspatercept) — erythroid maturation, MDS/beta-thal
• Camzyos (mavacamten) — cardiac myosin, HCM

Top Bristol-Myers Squibb trial indications

Condition / Indication	Trials
["Multiple Myeloma"]	6
["Schizophrenia"]	5
["Healthy Volunteers"]	5
["Myelodysplastic Syndromes"]	3
["Plaque Psoriasis"]	3
["Non-small Cell Lung Cancer (NSCLC)"]	3
["Relapsed or Refractory Multiple Myeloma"]	2
["Non-Small Cell Lung Cancer"]	2

Why monitor Bristol-Myers Squibb's clinical trial activity

BMS's PD-1/CTLA-4 combination program generates dozens of new combination trials annually. For any company developing new IO agents or solid tumor therapies, tracking when BMS starts a new Opdivo+Yervoy+X trial in your indication is critical competitive intelligence.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Bristol-Myers Squibb's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Bristol-Myers Squibb trials

• Sponsor normalization: Bristol-Myers Squibb may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is BMS's focus in oncology clinical trials?

BMS's oncology trials center on three platforms: Opdivo/Yervoy IO combinations (pan-tumor), CAR-T cell therapies (Breyanzi for B-cell lymphoma, Abecma for myeloma, next-generation BCMA/CD19 therapies), and selective kinase inhibitors. Their IO program remains the broadest in the industry by indication coverage.

How many BMS trials are currently recruiting?

Based on current ClinicalTrials.gov data, 71 Bristol-Myers Squibb-sponsored trials are actively recruiting patients across oncology, hematology, and cardiovascular programs.

Does DataLookout track the full BMS pipeline including legacy Celgene programs?

Yes. DataLookout normalizes Bristol-Myers Squibb, Celgene (which BMS acquired), and Juno Therapeutics under a single canonical entity where applicable, providing a unified view of the combined pipeline.